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SUMMARY 
 
Impact of Photodynamic Therapy (PDT) on human keratocytes and 
corneal endothelial cells in vitro 
 
Purposes: With increasing resistance of microorganisms to antibiotics, PDT may be a 
potential alternative in case of therapy resistant infectious keratitis. PDT is based on a 
photosensitizer activated by light of appropriate wavelength, which leads to 
generation of singlet oxygen and free radicals, responsible for the cytotoxic effect on 
microorganisms. Thus, it is important to determine the influence of PDT on human 
keratocytes and corneal endothelial cells. 
The purpose of this study was: 
l To evaluate the impact of PDT using the photosensitizer Ce6 on viability, 
apoptosis, proliferation and activation of human keratocytes, in vitro. 
l To investigate the impact of PDT using the photosensitizer Ce6 on the secretion 
of KGF, FGFb, VEGF, HGF and TGFβ1 of human keratocytes, in vitro. 
l To determine the impact of PDT using the photosensitizer Ce6 on viability, 
apoptosis and proliferation of human corneal endothelial cells (HCECs), in vitro. 
 
Methods: Primary human keratocytes were isolated by digestion in collagenase (1.0 
mg/ml) from human corneal buttons and cultured in DMEM/Ham's F12 medium 
supplemented with 10% fetal calf serum (FCS). An immortalized human corneal 
endothelial cell line was cultured in DMEM/Ham's F12 medium supplemented with 
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5% FCS. Cell cultures underwent illumination using red (670 nm) light for 13 minutes 
with a dose of 24 J/cm2 following exposure to 0 nM-64 µM concentrations of Ce6 in 
the culture medium.  
Twenty-four hours after PDT, human keratocyte and HCECs viability was evaluated 
by the Alamar blue assay, apoptosis and total DNA content of the cells using the 
APO- DIRECT TM Kit and cell proliferation by the BrdU Cell Proliferation Assay Kit.  
CD34 and alpha smooth muscle actin (α-SMA) expression of human keratocytes was 
analysed using flow cytometry (FACS) after illumination following exposure to 50, 
150 and 250 nM concentrations of Ce6 in the culture medium. In addition, five and 
twenty-four hours after illumination following exposure to 100 nM concentration of 
Ce6, the secretion of KGF, FGFb, VEGF, HGF and TGFβ1 of human keratocytes was 
measured by enzyme-linked immunoabsorbent assay (ELISA). 
  
Results: Using Ce6 or illumination only, we did not detect significant changes of 
human keratocyte and HCECs viability, apoptosis and proliferation. Following PDT, 
viability and total DNA content of human keratocytes decreased significantly above 
100 nM and 150 nM Ce6 concentration (P<0.01; P<0.01), respectively. The 
percentage of apoptotic keratocytes increased significantly from 250 nM Ce6 
concentration (P<0.01) and proliferation of keratocytes decreased significantly 
(P<0.05) above 100 nM concentration of Ce6 after PDT.  
Using Ce6 or illumination only, CD34 and α-SMA expression of human keratocytes 
did not change significantly. Twenty-four hours after PDT, the percentage of α-SMA 
positive human keratocytes decreased significantly at 250 nM concentration of Ce6 
(P=0.02).  
Compared to untreated controls, FGFb secretion of human keratocytes increased 
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(P<0.01) and HGF expression decreased (P<0.01) significantly 5 hours after PDT, 
whereas KGF, VEGF, and TGFβ1 secretion remained unchanged. Twenty-four hours 
following PDT, KGF secretion decreased (P<0.01) significantly, while FGFb, HGF, 
VEGF and TGFβ1 concentrations did not differ markedly from untreated controls. 
In HCECs, viability and total DNA content decreased significantly above 150 nM Ce6 
concentration (P<0.01; P<0.05). The percentage of apoptotic HCECs increased 
significantly from 250 nM Ce6 concentration (P<0.01) and proliferation of 
endothelial cells decreased significantly (P<0.05) above 100 nM concentration of Ce6 
after PDT. 
 
Conclusions: 
l PDT using Ce6 decreases viability and proliferation, suppresses myofibroblastic 
transformation and triggers apoptosis of human keratocytes, in vitro. 
l PDT triggers FGFb and inhibits HGF secretion of human keratocytes 5 hours and 
inhibits KGF secretion 24 hours following treatment. 
l PDT using Ce6 decreases viability and proliferation, and also triggers apoptosis 
of HCECs, in vitro.  
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ZUSAMMENFASSUNG  
 
Einfluss der photodynamischen Therapie (PDT) auf humane 
Keratozyten und korneale Endothelzellen in vitro 
 
Ziele: Durch die zunehmende Resistenzbildung von Bakterien gegenüber Antibiotika 
kann die Behandlung mit Photodynamischer Therapie (PDT) ein Verfahren zur 
Therapie einer infektiösen Keratitis darstellen. Die Wirkung der PDT basiert auf der 
Kombination eines von einer bestimmten Wellenlänge angeregten 
Photosensibilisators und des dadurch resultierenden Zelltodes durch freie 
Sauerstoffradikale. Aufgrund dieser Wirkungsweise ist es wichtig, den Einfluss der 
PDT auf humane Keratozyten und korneale Endothelzellen zu evaluieren. 
Die Ziele dieser Studie waren: 
l Den Einfluss der PDT unter Verwendung des Photosensibilisators Ce6 auf die 
Viabilität, Apoptose, Proliferation und Aktivierung kultivierter humaner 
Keratozyten auszuwerten. 
l Die Wirkung der PDT unter Verwendung des Photosensibilisators Ce6  auf die 
Sekretion von KGF, FGFb, VEGF, HGF und TGFβ1 zu untersuchen. 
l Den Einfluss der PDT unter Verwendung des Photosensibilisators auf die 
Viabilität, Apoptose und Proliferation humaner kornealer Endothelzellen (HCECs) 
in der Zellkultur auszuwerten.  
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Methoden: Humane primäre Keratozyten wurden durch enzymatische Behandlung 
mit Collagenase A (1,0 mg/ml) aus humanen Korneoskleralscheiben isoliert und in 
DMEM/Ham’s F12 Kulturmedium, versetzt mit 10% fetalem Kälberserum kultiviert. 
Die immortalisierte humane korneale Endothelzelllinie wurde in DMEM/Ham’s F12 
Kulturmedium, versetzt mit 5% fetalem Kälberserum kultiviert. Die Zellkulturen 
wurden mit Ce6 in einer Konzentration von 0 nM-64 µM für 30 Minuten inkubiert 
und anschließend mit einer Wellenlänge von 670 nm und einer Energiedosis von 24 
J/cm2 für 13 Minuten bestrahlt.  
24 Stunden nach der Behandlung erfolgte die Messung der Viabilität der humanen 
Keratozyten und der kornealen Endothelzellen mit dem AlamarBlue assay, die 
Proliferation wurde mit einem Zell-Proliferations-ELISA bestimmt, und die Apoptose 
durchflusszytometrisch mit dem APO-DIRECTTM Kit ermittelt. 
Die Erfassung der Expression von CD34 und alpha smooth muscle actin (α-SMA) 
erfolgte durchflusszytometrisch (FACS) 24 Stunden nachdem die humanen 
Keratozyten mit Ce6 in den Konzentrationen von 0, 50, 150 und 250 nM für 30 
Minuten inkubiert und anschließend mit einer Wellenlänge von 670 nm für 13 
Minuten bestrahlt wurden.  
Fünf und 24 Stunden nach der Behandlung (mit einer Konzentration von 100 nM Ce6) 
wurde die Sekretion von KGF, FGFb, VEGF, HGF und TGFβ1 mit einem enzym- 
linked immunoabsorbent assay (ELISA) photometrisch analysiert. 
 
Ergebnisse: Die ausschließliche Anwendung von Ce6 oder Bestrahlung führte nicht 
zu einer signifikanten Veränderung der Viabilität, Apoptose oder Proliferation bei den 
humanen Keratozyten oder den kornealen Endothelzellen. Die Viabilität und der 
DNA-Gehalt der humanen Keratozyten sanken mit einer Ce6 Konzentration von 100 
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nM und 150 nM signifikant (P<0,01; P<0,01). Die Apoptoserate der Keratozyten stieg 
ab einer Ce6 Konzentration von 250 nM Ce6 signifikant an (P<0,01). Darüberhinaus 
führte die PDT ab einer Ce6 Konzentration von 100 nM zu einer signifikant 
verminderten Proliferationsrate der Keratozyten (P<0,05). 
Unter Verwendung von entweder nur Ce6 oder nur Bestrahlung ergaben sich keine 
Veränderungen der Expression von CD34 und α-SMA der Keratozyten. 
Vierundzwanzig Stunden nach PDT mit 50-250 nM Ce6 blieb die CD34 Expression 
unverändert, während der Prozentsatz von α-SMA positiven Keratozyten bei 250 nM 
Ce6 signifikant sank (P=0,01).  
Fünf Stunden nach der Behandlung blieb die Sekretion von KGF, VEGF und TGFβ1 
unverändert, während die FGFb Sekretion der Keratozyten anstieg (P<0,01), und die 
HGF Sekretion sank (P<0,01). Nach 24 Stunden sank die KGF Sekretion signifikant 
(P<0,01), während die Konzentrationen von FGFb, HGF, VEGF und TGFβ1 im 
Vergleich zu den Kontrollen unverändert blieben. 
Bei den kornealen Endothelzellen sanken die Viabilität und der DNA-Gehalt ab einer 
Ce6 Konzentration von 150 nM signifikant (P<0,01). Die Apoptoserate der kornealen 
Endothelzellen stieg ab einer Ce6 Konzentration von 250 nM Ce6 signifikant an 
(P<0,01). Darüberhinaus führte die PDT ab einer Ce6 Konzentration von 100 nM zu 
einer signifikant verminderten Proliferationsrate der Endothelzellen (P<0,05). 
 
Schlussfolgerung:  
l PDT unter Verwendung von Ce6 senkt die Viabilität und Proliferationsrate, 
hemmt die myofibroblastische Transformation und steigert die Apoptoserate von 
humanen Keratozyten in der Zellkultur. 
l PDT steigert die Sekretion von FGFb und vermindert die Sekretion von HGF von 
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Keratozyten 5 Stunden nach der Behandlung, 24 Stunden nach PDT zeigt sich 
eine erniedrigte KGF Sekretion. 
l PDT unter Verwendung von Ce6 senkt die Viabilität und Proliferationsrate von 
kornealen Endothelzellen, und steigert deren Apoptoserate in der Zellkultur. 
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1    INTRODUCTION 
 
The eye, called the window of the soul is a sensory organ for the perception of light 
stimuli. A healthy, clear cornea is essential for good vision of the eye as it is the 
anterior front part of the eye in front of lens, vitreous body and retina. The cornea 
contributes to approximately three-quarters of the total optical power of the eye. 1 
Corneal opacities due to infection, injury or any other ocular surface diseases interfere 
with vision.  
Infectious keratitis may be caused by bacteria, fungi, viruses and protozoa. If the 
appropriate diagnosis and antimicrobial treatment are delayed, only about 50% of 
eyes gain good visual recovery. 2 Furthermore, treatment failure may even happen 
despite the use of broad spectrum antibiotics in clinical routine. Therefore, researchers 
try to explore potential alternative therapies for infectious keratitis, including 
especially those with resistance to antimicrobial treatment.  
In this work, we describe the challenges in diagnosis and treatment of infectious 
keratitis. We also define PDT, which may be considered as a potential alternative or 
additional antimicrobial treatment modality in infectious keratitis. 
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1.1    Corneal anatomy 
 
1.1.1   General aspects  
The normal cornea is mostly horizontally elliptical with an average diameter of 11.5 
mm vertically and 12.0 mm horizontally. The average thickness of the central cornea 
is 0.54 mm, and it becomes thicker towards the periphery. 1 
The cornea is free of blood vessels and is nourished from the aqueous humor of the 
anterior chamber and through the tear fluid. The cornea is innervated through a 
subepithelial and a deeper stromal plexus, which are richly supplied by numerous 
sensory nerve endings of the first division of the trigeminal nerve. 
 
1.1.2   Corneal layers  
The human cornea consists of five layers, from anterior to posterior the epithelium, 
Bowman's layer, the stroma, Descemet's membrane and the endothelium. Each layer 
plays an important and distinct role in corneal physiology and pathophysiology.  
 
1) Epithelium 
The corneal epithelium is the outermost layer of the cornea. It is on average 
0.04-0.06 mm thick and is composed of multiple epithelial cell layers. There are 
three different types of cells: the basal, wing and squamous cells. The basal cells 
are adhered to the underlying basement membrane. Above them, there are two or 
three layers of wing cells and two layers of superficial squamous cells, adjacent 
to the tear film. The superficial cells with many microplicae and microvilli are 
involved in the stabilization of the tear film and the absorption of nutrients. In 
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addition, highly resistant tight junctions formed between neighboring epithelial 
cells provide a protective barrier, which is essential for good corneal optical 
properties during continuous renewal of the corneal epithelium. 3,4 
Limbal stem cells are indispensable for the maintenance of a healthy corneal 
surface. These are principally located at the basal layer of the palisades of Vogt 
at the cornea conjunctival junction. 5-7 The deficiency of limbal stem cells may 
result in conjunctival epithelial ingrowth, neovascularization, chronic 
inflammation or recurrent epithelial erosions and defects. 8,9 
  
2) Bowman's layer 
The corneal Bowman’s layer is an acellular superficial layer of the stroma 
consisting of collagen fibers. The Bowman's layer is a visible indicator of 
ongoing stromal-epithelial interactions in the cornea. However, its critical 
function in corneal physiology is still unclear. 10 
 
3) Stroma 
The stroma is the transparent middle layer of the cornea, which is about 
0.40-0.50 mm thick. It accounts for about 90% of the total corneal thickness. The 
corneal stroma is also called substantia propria. It comprises arranged collagen 
fibers with sparsely distributed interconnecting keratocytes. The maintenance of 
lattice arrangement and spacing of collagen fibrils is critical for the transparency 
of the cornea. 11,12 
Under normal circumstances, stromal keratocytes are rarely dividing cells. 
However, keratocytes can proliferate and migrate in case of tissue damage and 
transform into activated fibroblasts or/and myofibroblasts. They also produce 
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collagen and proteoglycans for repair when an injury occurs in the stroma. 13  
 
4) Descemet's membrane 
The Descemet's membrane consists of a fine latticework of collagen fibrils, 
which are distinct from the collagen lamellae of corneal stroma. It serves as a 
protective barrier against infection and injuries. Descemet's membrane contains 3 
zones: an anterior perinatal zone which is deposited in utero; a middle "normal" 
adult zone; a posterior abnormal zone, which serves as a modified basement 
membrane for the endothelium. 14 
 
5) Endothelium 
The corneal endothelium is approximately 0.005 mm thick. It is a monolayer of 
cells at the posterior surface of the cornea. Endothelium is essential in keeping 
the cornea transparent, as it is responsible for a dynamic balance between a 
“leaky” barrier for fluid moving into the stroma and a fluid pump to actively 
move fluid from the stroma back into the anterior chamber of the eye. 15-17  
Corneal endothelial cells have a limited regenerative potential in vivo. The cell 
density in human adult is approximately 2500 cells/mm². This number steadily 
decreases with advancing age, 18 diseases 19 and intraocular surgery. 20 
Maintenance of corneal transparency can be lost when endothelial cell density is 
below a critical level.   
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Figure 1. The human cornea in cross-section. 4 At the outer surface of the cornea, 
there is an epithelial layer adhered to a basement membrane above Bowman's layer. 
The stromal layer is sparsely populated with keratocytes. The single sheet of 
endothelial cells sits on Descemet's membrane. 
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1.2    Infectious keratitis 
 
1.2.1   Definition of infectious keratitis 
Infectious keratitis is an inflammatory condition of the cornea, characterized by 
inflammation in any layer of the cornea caused by an infection involving bacteria, 
viruses, fungi or protozoa. 1 Infectious keratitis is an emergency condition with 
patients often suffering from significant pain, distress, and acute visual loss.  
 
1.2.2   Epidemiology 
The incidence of infectious keratitis per 100 000 person-years in the developed world 
was 3.6 in the West of Scotland, 21 6.3 in Hong Kong 22 and 27.6 in Northern 
California. 23 However, it has been increasing due to higher rates of contact lens use. 
In Northern California, the incidence was 14.0 in non-contact lens wearers, whereas 
130.4 in contact lens wearers. 23 The incidence of acanthamoeba keratitis is also in 
closed association with contact lens use and it was 14.9 per 100 000 soft contact lens 
wearers. 21 In developed countries, herpetic eye disease is the most common cause of 
infectious keratitis, about 60% of infectious keratitis in developed countries may be 
the result of herpes simplex virus. 1 
The incidence of infectious keratitis per 100 000 person-years in the developing world 
is considerably higher, e.g. it was 113 in India 24 and 799 in Nepal. 25 Among severe 
infectious corneal ulcers, fungal keratitis is the most common infectious keratitis in 
the developing countries like China, India and Nepal. 25-27 One retrospective analysis 
from south India, aiming to determine the prevalence of microbial pathogens causing 
keratitis, has shown that 32.7% of infectious keratitis was due to bacterial, 34.4% due 
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to fungal aetiology. 27 Meanwhile, one epidemiologic study from north China between 
1999 and 2004 on infectious keratitis has reported of 61.9% fungal, 12.2% bacterial 
and 1.4% acanthamoeba keratitis and no pathogens could be isolated in 24.5% of the 
cases. 26 
 
1.2.3   Etiology 
The risk factors for infectious keratitis include overnight or extended wear of contact 
lenses, orthokeratology lenses, ocular trauma, ocular surface disease (including atopic 
or vernal keratoconjunctivitis and blepharitis), previous ocular surgery, previous 
keratitis (herpes simplex keratitis), systemic diseases (diabetes mellitus, rheumatoid 
arthritis) and the use of topical corticosteroids. 22,28-33 However, in about 7.9% of 
individuals with infectious keratitis no identiﬁable risk factors could be verified. 29 
Among infectious keratitis cases, the contact lens related and traumatic keratitis are 
more common in younger patients, whereas the keratitis associated with prior ocular 
surgery or ocular surface disease is more common in older persons. 34  
Common causative organisms associated with bacterial keratitis are from the gram 
positive group Staphylococcus aureus (SA) and coagulase-negative Staphylococcus 
(CNS) and from the gram-negative group Pseudomonas aeruginosa (PA). Some 
studies reported that PA is the most common organism in positive cultures of corneal 
scrapings: 20.1% in China, 35 25.7% in South Florida 36 and 17% in Brisbane, 
Australia. 34 However, this prevalence of causative organisms is not in accordance 
with other geographical regions, which found CNS to be the most common organism 
30% isolated on corneal scrapings in six centers in the United Kingdom between 2003 
and 2006 37 and 21.8% of 201 cases in France between 1998 and 1999. 38 SA (26.7%) 
was the most common isolated pathogen from bacterial keratitis in South India 
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between 2002 and 2007. 39 Green et al. 34 reported that PA (55%) is the most common 
pathogen isolated from contact lens related cases, SA (29%) is more common in 
ocular surgery related cases, and negative culture isolates (59%) are more common in 
traumatic keratitis. 
Among fungal keratitis, filamentous fungi are the most common causative 
microorganism associated with trauma caused through plants in the developing 
countries, 26,27,40,41 and contact lens wear in the United States, 42,43 whereas yeast is 
more frequently the causative pathogen in patients with ocular surface diseases. 
 
1.2.4   Clinical features and diagnosis 
Early symptoms of infectious keratitis include redness, tearing, pain, sensitivity to 
light, purulent discharge, a white corneal infiltrate and decreased vision. However, 
certain signs may also be unique or specific presentations for one special kind of 
infectious keratitis. 
In fungal keratitis serrated margins, raised slough, dry texture, satellite lesions and 
coloration other than yellow were observed more frequently. 44 The probability of 
fungal infection was 63% if one clinical feature was present, increasing to 83% if all 
three features were present. 
In cases of acanthamoeba keratitis the clinical features are photophobia, 
disproportionate pain of the cornea, a radial pattern of perineural infiltrates, ring 
infiltrates, a central epithelial loss with stromal thinning and occasionally progression 
to corneal melt. 45 Acanthamoeba keratitis, with the common disciform epithelial and 
stromal infiltrate features, was commonly initially diagnosed as herpes simplex virus 
(HSV) or even fungal keratitis. 45 
A provisional diagnosis for infectious keratitis can be made using the history and the 
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clinical features, although a definitive diagnosis requires conventional methods of 
culture and histology, advanced noninvasive techniques 46-48 and molecular techniques 
for diagnosis of viral and fungal keratitis. 49,50 Corneal scraping provides samples for 
an etiological diagnosis, moves necrotic tissue and enhances antibiotic penetration.  
In the absence of a clear diagnosis, diagnostic treatment ex juvantibus can even be 
considered. If the infectious keratitis is running with an atypical presentation and 
course, or it is found unresponsive to the initial medical treatment, the possibility of a 
co-infection should be considered. 51  
 
1.2.5   Treatment 
Antimicrobial agents should be started as soon as diagnostic test were performed. The 
initial treatment should generally use broad spectrum antibiotics covering most 
common pathogens. More selective agents are applied if the results of the diagnostic 
tests are available. Topical steroids, if applied, should always be used with caution as 
they may promote replication of some types of organisms, specifically herpes simplex 
virus and fungi. 
Besides, surgical treatment is also of great importance for some conditions of 
infectious keratitis, including removal of infected epithelium to facilitate 
re-epithelialization and eye drop absorption, transplantation of amniotic membrane or 
even keratoplasty. 1  
 
1.2.6   Antibiotic resistance and management 
The most common factors contributing to increasing trend of antimicrobial drug 
resistance among ocular organisms are the overuse of drugs for systemic infection and 
the widespread and sometimes inappropriate use of topical antibiotics for eye disease. 
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52-55 Studies have reported on the increasing resistance of gram positive organisms, 53 
pseudomonas 56 and atypical mycobacteria. 57 Besides the increased resistance during 
the past decade, the incidence of gram positive organisms, specifically SA, has been 
increasing significantly. 36,58,59 One example for resistant microorganisms is the 
methicillin-resistant Staphylococcus aureus (MRSA), which is known for its resistance 
to all available penicillins and other β-lactam antibiotics.  
In the 2009 Antibiotic Resistance Monitoring in Ocular MicRorganisms (ARMOR) 
surveillance study, 60 the common ocular isolates of SA and CNS were collected from 
34 institutions across the United States and analysed by testing the antibacterial 
susceptibility profile of these microrganisms. The results showed that 39% of SA and 
52.8% CNS isolates were resistant to methicillin, and 46.5% of SA and 58.3% of CNS 
isolates were nonsusceptible to 2 or more antibacterial drug classes. Almost all of the 
MRSA isolates were resistant to azithromycin and nearly 80% were resistant to 
ciprofloxacin. With the growing evidence of resistance to current antibiotics, 
ophthalmologist try to select a best initial treatment for infectious eye disease with the 
development of new antibiotics, or effective therapeutic options to treat infectious 
keratitis. Fortunately, all the through ARMOR study identified SA and CNS isolates 
were susceptible to vancomycin.  
Furthermore, the use of topical fourth-generation fluoroquinolones and photodynamic 
therapy (riboflavin/ultraviolet crosslinking) are considered as potential alternatives in 
the management of infectious keratitis. 61,62 Notably, the antimicrobial efficacy of 
riboflavin/ultraviolet-A crosslinking for SA, MRSA, PA and fungal isolates was 
determined. 63,64  
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1.3    Photodynamic Therapy 
 
1.3.1   Definition of PDT 
Photodynamic therapy (PDT) is a promising treatment for cancer and other diseases. 
PDT involves the application of a photosensitizer (PS) compound followed by 
exposure to light of appropriate wavelength. It results in production of reactive 
oxygen species (ROS) leading to cell death and/or tissue damage. 
The first observation of tissue photochemical sensitization by the interaction between 
light and a chemical drug was reported by Raab 65 in 1900. He discovered a lethal 
effect on Infusoria, a species of paramecium, dependent on a combination of acridine 
red and light. Furthermore, Tapperner and Jesionek 66 used a combination of topically 
applied fluorescent substance of eosin and white light to treat skin tumors, which was 
considered as the first medical application of PDT. Over the past century, PDT was 
widely used in clinical treatment. The combination of cell or tissue selective PS 
uptake and local light exposure provided a potential effective approach to cancer 67 
and infectious disease 68 treatment. It has efficient cytotoxicity, but limited damage to 
the surrounding normal cells or tissues. 
 
1.3.2   Photochemistry of PDT 
The photochemical reaction is represented at the Jablonski diagram. 69 Through 
illumination with light of appropriate wavelength, the PS in a singlet state (S0) is 
excited from ground state to the first excited singlet state (S1) and the second excited 
singlet state (S2).  
Following excitation, the molecule can relax back to the ground state by emitting 
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fluorescence or through nonradioactive relaxation quenching processes, but can also 
be converted to the excited triplet state (T1) with a longer life-time. The T1 can return 
to the ground state by emitting phosphorescence and can also undergo type I (electron 
transfer) and/or type II (energy transfer) reactions to produce highly reactive oxygen 
species (ROS). 67,70  
 
 
Figure 2. Jablonski diagram representing the excitation and relaxation of a 
photosensitizer (PS), with type I and type II photoreactions. S0 = ground singlet state; 
S1 = first excited singlet state; S2 = second excited singlet state. 69 
 
Generally, in the type I reaction free oxygen radicals formed by the electron-transfer 
reaction between the excited triplet state and a substrate molecule produce ROS 
including hydrogen peroxide (H2O2) and superoxide anion (O2-). In the type II 
reaction, the direct energy-transfer of T1 leads to the formation of highly reactive 
singlet oxygen (1O2). Singlet oxygen is an electronically excited state of molecular 
oxygen and has a short life-time in biologic systems and a short radius of action 71. 
Thus, the reaction of reactive singlet oxygen can lead to a localized response without 
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damaging distant cells or tissues. It is not only generally accepted that Type II 
reactions play a dominant effect in application of PDT in cancer treatments, 72-75 but 
also seems to be the major pathway in reduction of organism damage in antimicrobial 
PDT. 76-78
 
1.3.3   Light sources 
Visible light has a wavelength spectrum within the range of approximately 400-700 
nm between the invisible ultraviolet (UV) and the invisible infrared rays (IR). 79
 
 
Figure 3. http://en.wikipedia.org/wiki/File:EM_spectrum.svg
 
The use of light as a therapeutic agent originates from the ancient Egypt, India and 
China. It was used to treat skin diseases such as psoriasis, vitiligo and also in cancer 
and psychosis. 80
PDT requires a source of light to activate the PS. The activating light is most often 
generated by lasers as they possess a high power density, a monochromatic character 
(light of one wavelength) and high local and temporal coherence. 81,82 The energy 
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absorbed by the PS in a volume of tissue, can be calculated exactly if the fluence rate 
of light, drug concentration and the absorption coefficient are defined at all times in 
the concrete tissue volume. 83 During PDT, the depth of light penetration into the 
tissue varies with the optical properties of the tissue and the wavelength of light, 
which may be a critical factors contributing to efficacy of PDT. 84,85 
 
1.3.4   Photosensitizers (PSs) 
The majority of PSs possess a porphyrin ring structure, which is similar to that of 
chlorophyll or heme in hemoglobin. The structure of PSs plays a key role in their 
success as a PDT agent. The PSs absorb light of a specific wavelength, which results 
in the transfer and translation of light energy into chemical reaction in the presence of 
molecular oxygen and then in production of singlet oxygen or superoxide. These 
molecules induce cell damage through direct or indirect cytotoxicity. 86 Therefore, the 
PS is considered to be a critical component in PDT procedures. 
Since the first observation of tissue photochemical sensitization reported by Raab 65 in 
1900, many new PSs were synthesized and analysed over the past century. 
In clinical application, PSs are divided into three families such as porphyrin, 
chlorophyll and dye (Table 1). Generally, the porphyrins, developed in the 1970s and 
early 1980s, are called first generation PSs. Porphyrin derivatives were developed 
since the late 1980s and are called second generation PSs. Third generation PSs are 
available drugs modificed with biologic conjugates to increase the affinity of the PS 
for the tissue. 87,88 The fact that different generations of PSs exist does not mean that 
newer generation drugs in clinical application are better than older drugs. 86  
 
 
INTRODUCTION                                                    15 
  
 
Table 1. Photosensitizer families 
1.  Porphyrin platform 
    Hematoporphrin derivative (HpD) 
    Benzoporphrin derivative (BpD) 
    5-aminolevulinic acid (ALA) 
    Texaphrins 
2.  Chlorophyll platform 
    Chlorins  
    Punpurins 
    Bacteriochlorins  
3.  Dyes 
    Phtalocyanine  
    Napthalocyanine  
 
Administration of Hematoporphyrin derivative (HpD) followed by local exposure to 
red light performed by Dougherty et al. 89 resulted in a partial or complete tumour 
necrosis in 111 of 113 malignant tumors. To date, HpD is one of the successful PSs in 
the clinical practice and it is an accepted PDT drug, which can be used for early 
(superficial) bladder cancer in several countries. In addition, porphyrin has a weak 
absorption maximum at low wavelength (630 nm) as it results in poor tissue 
penetration of light. 
Chlorin e6 (Ce6) is a natural compound and can be produced by Live chlorella. It is a 
promising second generation photosensitizer with its appropriate photophysical 
properties. In addition, Ce6 has a long lifetime in its photoexcited triplet state and a 
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high absorption in the red range of the visible spectrum (longer than 630 nm). PDT 
using the photosensitizer Ce6 is currently applied an alternative therapeutic option for 
a variety of malignant tumors both in vitro and in vivo. 90-93 
 
 
 
Figure 4. Chlorin e6: 2-[(7S, 8S)-3-Carboxy-7-(2-carboxyethyl)-13-ethenyl-18-ethyl- 
7, 8-dihydro-2, 8, 12, 17-tetramethyl-21H, 23H-porphin-5-yl] acetic acid. 
(http://www.medkoo.com/bio-reagents/ChlorinE6.htm) 
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1.4    PDT in infectious keratitis 
  
The widespread use of antibiotics leads to the increasing resistance of microorganisms 
to antibiotics. Therefore, the development of potent and safe antimicrobial agents in 
order to prevent or treat infectious diseases is necessary and led to the use of 
bacteriophages, 94 naturally occurring or synthetic antimicrobial peptides 95 and 
antibacterial PDT. 68,96,97   
During 1960’s, irreversible photosensitization of entero and even other viruses was 
described by Wallis and Melnick. 98-101 In 1972, Moore et al. 102 first demonstrated 
that herpetic keratitis was rapidly resolved following PDT using the PS proflavine in a 
rabbit model. In contrast, a clinical trial has shown that there was no significant 
difference in the number of healed patients, the mean healing time, or the number of 
recurrences of the herpetic corneal ulcers treated by PDT. 103 
In vitro studies demonstrated that Acanthamoeba isolates are most sensitive for 
radiation exposure combined with one potential drug, such as Hypocrellins B, 104 
Methylene blue, 105 Tetracationic Zn(II)-phthalocyanine (RLP068) 106 and Riboflavin. 
107 The evaluation of clinical cases also revealed that the adjunctive use of 
riboflavin/UVA crosslinking seems to be a potential alternative for Acanthamoeba 
keratitis. 108  
The anti-fungal properties of porphyrins have been investigated extensively since the 
early 1980s. 109 Although PDT using phenothiazinium, porphyrin or riboflavin is 
effective against fungal isolates from corneal scrapings such as Candida albicans, 
Fusarium species, and Aspergillus fumigatus, in vivo animal studies and human trials 
are limited. 110,111 Li et al. 112 recently presented eight cases with fungal keratitis. 
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None of them required corneal transplantation, following riboflavin/UVA crosslinking: 
visual acuity improved in six cases, remained unchanged and deteriorated in one case. 
PDT is capable of killing bacteria both in vitro and in vivo conditions. 63,113-116 
Therefore, it may be also an alternative in case of therapy resistant bacterial keratitis. 
Martins et al. 63 conducted an in vitro study to demonstrate the antimicrobial 
properties of riboflavin/UVA crosslinking against common pathogens. They found 
this treatment to be effective against SA, Staphylococcus epidermidis (SE), MRSA, PA, 
multidrug-resistant Pseudomonas aeruginosa (MDRPA) and drug-resistant 
Streptococcus pneumoniae (DRSP). Several clinical studies also demonstrated the 
effectiveness of riboflavin/UVA crosslinking as PDT in treatment of bacterial keratitis. 
117-119 
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1.5    Thesis aims 
 
With increasing resistance of microorganisms to antibiotics, PDT may be a potential 
alternative in case of therapy resistant infectious keratitis. PDT is based on a 
photosensitizer activated by light of appropriate wavelength, which leads to 
generation of singlet oxygen and free radicals, responsible for the cytotoxic effect on 
microorganisms. Thus, it is important to determine the influence of PDT on human 
keratocytes and corneal endothelial cells. 
 
The purpose of our study was: 
 
l To evaluate the impact of PDT using the photosensitizer Ce6 on viability, 
apoptosis, proliferation and activation of human keratocytes, in vitro. 
 
l To investigate the impact of PDT using the photosensitizer Ce6 on the secretion 
of KGF, FGFb, VEGF, HGF and TGFβ1 of human keratocytes, in vitro. 
 
l To determine the impact of PDT using the photosensitizer Ce6 on viability, 
apoptosis and proliferation of human corneal endothelial cells (HCECs), in vitro. 
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2    MATERIALS AND METHODS 
 
2.1    Reagents 
 
Dulbecco's Modified Eagle Medium: (Nutrient Mixture F-12 (DMEM/F12)); fetal 
bovine serum (10%); P/S (1% of 10,000 U/ml penicillin and 10 mg/ml streptomycin); 
0.05% trypsin/0.02% ethylenediaminetetra-acetic acid (EDTA) were purchased from 
PPA Laboratories (Pasching, Austria), Alamar blue from Invitrogen (Karlsruhe, 
Germany) and propidium iodide from Molecular Probes, Inc. (Eugene, Oregon, USA). 
Collagenase A, Dispase II and Cell Proliferation ELISA-BrdU (colorimetric) were 
obtained from Roche Diagnostics (Mannheim, Germany). Fibronectin was from 
Sigma Chemie (Deisenhofen, Germany). The APO-DIRECTTM Kit and all tissue 
culture plastics were from BD Biosciences (Heidelberg, Germany). Mouse 
Anti-Human CD34-FITC was from Biozol (Eching, Germany) and Anti-alpha smooth 
muscle Actin (α-SMA) antibody (FITC) was from Abcam (Cambridge, USA). KGF 
was from Blue Gene Biotech (Shanghai, China), FGFb, VEGF, HGF were from 
RayBiotech (Norcross, USA) and TGFβ1 was from Gen-Probe Incorporated (San 
Diego, USA). Ce6 was purchased from ORPEGEN Pharma (Heidelberg, Germany). 
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2.2    Cell culture 
 
2.2.1   Isolation of primary human keratocytes 
Human corneas were obtained from the Saarland University Hospital LIONS Eye 
Bank. Human keratocytes were isolated as described previously. 120,121  
In short, the human corneoscleral buttons were aseptically rinsed in phosphate- 
buffered saline (PBS) before removal of the endothelium including the Descemet’s 
membrane by sterile surgical disposable scalpel. A central corneal button with 
epithelium was cut using a 8 mm Barron’s trephine and thereafter incubated in culture 
medium containing 2.4 U/ml Dispase II for 4 hours at 37 °C. In the following, the 
corneal button was washed with PBS for several times and the already loose corneal 
epithelium was removed with disposable surgical scalpel. The remaining corneal 
stroma was incubated in culture medium with 1 mg/ml collagenase A for 8-10 hours 
at 37 °C. The digested tissue and cells were pipetted three times and centrifuged at 
800 g for 7 minutes and finally resuspended in 1 ml culture medium, which consisted 
of basic medium (DMEM/F12) supplemented with 10% FBS and 1% P/S. The cell 
suspension was seeded in 6-well plates and the medium was changed 24 hours after 
seeding.  
Medium was changed every 2 to 3 days until keratocytes reached confluence. The 
cells were subcultured in 25 cm2 culture flasks after 5 to 10 days following dispersal 
with 0.05 % trypsin-EDTA for 3 to 5 minutes and the passage 4 to 8 of cells was used 
for experiments.  
 
 
MATERIALS AND METHODS                                        22 
  
2.2.2   Culture of Human Corneal Endothelial Cells (HCECs) 
An immortalized human corneal endothelial cell line (HCEC-12, Technical University 
Dresden, Dresden, Germany) (previously established by SV40 transfection) prepared 
from a healthy cornea of a 91-year-old Caucasian woman was used for the 
experiments. Cells were cultured in DMEM/Ham's F12 medium supplemented with 
5% FCS and 1% P/S. The culture plates were coated using 20 µg/ml fibronectin. 
Medium was changed every 2 to 3 days until HCECs reached confluence, and then the 
cells were subcultured following dispersal with 0.05% trypsin-EDTA for 3 to 5 
minutes and passages 4-25 of HCECs were used for experiments.  
 
2.3    Photodynamic Therapy (PDT) 
 
2.3.1   PDT of primary human keratocytes 
Human keratocytes were seeded in tissue culture plates and allowed to grow for 48 
hours before photodynamic treatment. For viability, apoptosis and proliferation 
measurements, concentrations of photosensitizer ranged from 50 nM to 64 µM.  
Stock solution of Ce6 was prepared with 30 mM concentration. The different 
concentrations of fresh Ce6 were made using basic medium (DMEM/F12). Cells were 
washed with PBS once before and after incubation with different concentrations of 
Ce6 at 37 °C for 30 minutes. Following exposure to the photosensitizer Ce6, Ce6 
medium was replaced by basic medium, and then cells were exposed to red light (670 
nm) for 13 minutes with a dose of 24 J/cm2, Ce6 medium was replaced by 
DMEM/F12 after a washing step with PBS. As control groups, cells were incubated in 
the dark for 13 minutes after exposure to Ce6. After illumination, the cells were fed 
with culture medium and cultivated at 37 °C for 24 hours before measurements. 
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2.3.2   PDT of HCECs 
HCECs were seeded in tissue culture plates and allowed to grow for 48 hours before 
photodynamic treatment. For this experiment, concentrations of the photosensitizer 
ranged from 0 to 500 nM. Stock solution of chlorin e6 (Ce6) was prepared with 30 
mM concentration. The different concentrations of fresh Ce6 solution were made 
using basic medium (DMEM/F12). Cells were washed with PBS once before and after 
incubation with different concentrations of Ce6 at 37 °C for 30 minutes. Following 
exposure to the photosensitizer Ce6, Ce6 medium was replaced by basic medium, and 
then cells were exposed to red (670 nm) light for 13 minutes. After illumination, the 
cells were fed with culture medium and let grow at 37 °C for 24 hours before 
measurements. 
 
 
Figure 5. Illumination box (λ = 670 nm, 24 J/cm2) 
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2.4    Determination of cell morphology   
 
Twenty-four hours following PDT, morphological changes of keratocytes according 
to Seitz et al. 120 and HCECs were evaluated by inverted phase contrast microscopy 
(Eclipse TE2000-S, Nikon, Tokyo, Japan). 
 
2.5    Propidium iodide (PI) immunocytochemisty 
 
Human keratocytes or HCECs were seeded on cover glass in 6-well culture plates 
with a cell density of 7.5×103 cells/cm2. Twenty-four hours following PDT, cells were 
fixed on microscope slides with 70% methanol following two washing steps with PBS. 
Thereafter, the cells were washed with SSC buffer (2×) and incubated with 500 nM of 
PI solution for 3 minutes at room temperature. The nucleic acid staining of 
keratocytes and HCECs was analyzed with a fluorescence microscope (Axiovert 200, 
Carl Zeiss, Jena, Germany). 
 
2.6    Determination of viability (phototoxicity)  
 
Cell viability was evaluated using the Alamar blue assay as follows: Human 
keratocytes or HCECs were seeded in 24-well cell culture plates at concentration of 
7.5 × 103 cells/cm2 and 1.0 × 105 cells/well, respectively.  
At 24 hours after illumination, Alamar blue solution was diluted with culture medium 
for a final concentration of 10% and 500 µl of this solution was added to each well. 
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After 3 to 4 hours of incubation, 200 µl of conditioned culture medium from each well 
was transferred into two wells of 96-well plates. As a negative control, Alamar blue 
solution was added to a well without cells. Thereafter, all plates were exposed to an 
excitation wavelength of 560 nm and the emission at 616 nm was recorded using a 
Wallac 1420 Multilabel Counter (PerkinElmer Life Sciences, Wellesley, MA, USA). 
 
2.7    Flow cytometric analysis 
 
To determine the relative number of apoptotic cells (APO-DIRECTTM Kit), human 
keratocytes or HCECs were seeded in 6-well cell culture plates with a concentration 
of 7.5 × 103 cells/cm2 and underwent PDT as described above.  
They were harvested at 24 hours following PDT. First, the culture medium was 
discarded and the cells were trypsinized before centrifugation. Then, the cells were 
suspended in 1% paraformaldehyd at a concentration of 10 × 105 cells/ml and placed 
on ice for 30-60 minutes. Thereafter, cells were washed twice with PBS and stored for 
30 minutes at -20 °C following adding 1 ml ice cold 70% ethanol. After removing the 
ethanol carefully by aspiration, fixed cells were resuspended twice in 1 ml 
wash-buffer. The control cells and the probes were resuspended in 50 µl 
DNA-labeling-solution (FITC marked dUTP) and the cells were washed twice before 
resuspending the cell pellet in 500 µl PI/RNase staining buffer (0.3 ml for lower cell 
amount). Cells were incubated in the dark for at least 30 minutes at room temperature 
prior to analysis using a FACSCanto flow cytometer (BD Biosciences, Heidelberg, 
Germany). 
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2.8    Determination of cell proliferation 
 
The proliferation of the keratocytes or HCECs was determined with the cell 
proliferation ELISA-BrdU kit, by the measurement of BrdU incorporation in the 
newly synthesized cellular DNA. Keratocytes were plated at a density of 2 × 103 
cells/well and HCECs of 5 × 103 cells/well in a 96-multiwell plate with culture 
medium of 100 µl, respectively.  
PDT was performed as described before with 0, 100 nM and 250 nM Ce6 
concentrations. To detect the influence of PDT on the proliferation rate, we tested at 
24 hours before PDT, 2 hours and 24 hours after PDT. The test was performed 
according to the manufacturer’s protocol. BrdU was added to the keratocytes or 
HCECs at the tissue plates and incubated at 37 °C for 4 hours (BrdU incorporation). 
After removing the culture medium, the cells were fixed with FixDenat, provided with 
the test kit, followed by the incubation with anti-BrdU-POD, which binds the 
incorporated DNA. After adding the substrate solution, the immune complexes were 
detected using an ELISA reader, Model 550 (Bio-Rad Laboratories GmbH, Munich, 
Germany). 
 
2.9    Expression of CD34 and α-SMA of keatocytes 
 
Cells were seeded in 6-well cell culture plates with a concentration of 4.0 × 103 
cells/cm2 and underwent PDT as described above. They were harvested at 24 hours 
following PDT with 0 and 100 nM of Ce6 concentration.  
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First, the culture medium was discarded and the cells were trypsinized and washed 
with PBS. To demonstrate α-SMA, the cells were incubated with 0.5 ml PERM 
solution for 10 minutes, and then the cells were washed once with PBS followed by 
incubation with FITC-conjugated mouse monoclonal antibodies (IgG2a) against 
human α-SMA (100 µg/104 cells) for 30 minutes in dark at room temperature. For 
CD34, a FITC-conjugated monoclonal antibody (IgG1) was used directly at a 
concentration of 200 µg/ml followed by an incubation step for 30 minutes in dark at 
room temperature. To prove specificity of the staining, isotype control experiment for 
each primary IgG-subtype antibody was performed. In a following step, all cell 
preparations were washed twice with PBS and analysed using a FACSCanto flow 
cytometer (BD Biosciences, Heidelberg, Germany), and the evaluation was performed 
with WinMDI software (Version 2.9). 
 
2.10   Growth factor secretion of keratocytes 
 
Human keratocytes were seeded in 24-well cell culture plates with a concentration of 
7.5×103 cells/cm2 and underwent PDT with 0 and 100 nM Ce6 concentrations. They 
were harvested at five hours and twenty-four hours 24 hours following PDT.  
The concentration of KGF, FGFb, VEGF, HGF and TGFβ1 in each well was 
measured by taking a 100 µl aliquot of the supernatant of the wells. Measurements 
were performed by ELISA with the following measurement ranges: KGF: 31-2000 
pg/ml, FGFb: 102-10000 pg/ml, VEGF: 8-6000 pg/ml, HGF: 2.74-2000 pg/ml and 
TGFβ1: 30-2000 pg/ml. Measured concentrations below the above values were 
considered as zero. The growth factor concentrations were quantified by using a 
human recombinant KGF, FGFb, VEGF, HGF and TGFβ1 as standard. The 
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measurements were performed exactly following the manufactures’ ELISA-protocols. 
In each well, the concentration of the growth factors in the supernatant was 
standardized to the cell protein concentration of the respective well. The absorbance 
was measured at 450 nm (Model 550 Bio-Rad Laboratories GmbH, München, 
Germany). The experiments were repeated five times using keratocyte cultures of five 
donor corneas from different patients. 
After taking the supernatant for ELISA, the total protein concentration of each well 
was measured following detachment of the cells with 150 µl CelLytic™ M. Protein 
quantity was determined according to the method of Bradford, 122 which is based on 
the formation of a complex between the dye, Brilliant blue G and proteins in solution. 
The absorbance was measured at 595 nm and the concentrations were quantified using 
bovine serum albumin (BSA) as standard protein. 
 
2.11   Statistical Analysis  
 
Quantitative data were expressed as means ± standard deviation (mean ± SD). 
Statistical analysis was performed using the Mann-Whitney U-test for comparisons of 
the means of two independent groups. To compare data among three or more groups, 
one-way analysis of variance (ANOVA) followed by the Dunnett's test was performed. 
P<0.05 was considered statistically significant. 
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3    RESULTS 
 
3.1    Morphology 
 
3.1.1   Keratocyte morphology 
Twenty-four hours following application of the photosensitizer Ce6 without exposure 
to light, cells did not change morphology, and showed a low nuclear cytoplasmic ratio. 
After a combination of illumination and Ce6 exposure, the impact was dependent on 
the concentration of Ce6 (Figure 6). With higher Ce6 concentrations, the surviving 
cells have shown high nuclear-cytoplasmic ratio. With concentrations higher than 2 
µM, there were usually only few clusters of cohesive cells left. 
  
 
Figure 6. Inverted phase-contrast photomicrographs of human corneal keratocytes 24 
hours after exposure to PDT (original magnification 100×). Without illumination, the 
cell morphology remained unchanged with different concentrations of Ce6, while with 
illumination, cell shrinkage occurred and keratocytes became detached with 
increasing concentrations of Ce6. 
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3.1.2   Morphology of HCECs 
Twenty-four hours following application of the photosensitizer chlorin e6 without 
exposure to light, cells did not change morphology and showed a low nuclear 
cytoplasmic ratio. After a combination of illumination and Ce6 exposure, the impact 
was dependent on the concentration of Ce6 (Figure 7). With higher Ce6 
concentrations, the surviving cells showed a higher nuclear-cytoplasmic ratio due to 
shrinkage of the cells. 
 
 
Figure 7. Inverted phase-contrast photomicrographs of HCECs 24 hours after 
exposure to PDT (original magnification 100×). Without illumination, the cell 
morphology remained unchanged with different concentrations of Ce6, while with 
illumination, cell shrinkage occurred and HCECs became detached with increasing 
concentrations of Ce6. 
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3.2    Propidium iodide (PI) immunocytochemistry 
 
3.2.1   PI immunocytochemistry of keratocytes 
Figure 8 shows PI staining of keratocytes after PDT using different concentrations of 
Ce6. The prominent red fluorescence of viable cells decreased with increasing 
concentrations of Ce6, in presence of illumination. With Ce6 concentration of 2 µM, 
no PI uptake of the keratocytes could be detected.  
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Figure 8. PI staining of human keratocytes 24 hours following PDT. Twenty-four 
hours after PDT, without illumination, the PI uptake of keratocytes remained 
unchanged with different concentrations of Ce6, while with illumination, the PI 
uptake of keratocytes was decreased with increasing concentrations of Ce6. 
 
3.2.2   PI immunocytochemistry of HCECs 
Figure 9 shows PI staining of HCECs after PDT, using different concentrations of 
Ce6. The prominent red fluorescence of viable cells decreased with concentrations of 
Ce6 higher than 250 nM in the presence of illumination.   
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Figure 9. PI staining (red) of HCECs 24 hours following PDT. Twenty-four hours 
after PDT, without illumination, the PI uptake of HCECs remained unchanged with 
different concentrations of Ce6, while with illumination, the PI uptake of HCECs was 
decreased with increasing concentrations of Ce6. 
 
3.3    Viability 
 
3.3.1   Keratocyte viability 
Results of the Alamar blue assay are shown in Figure 10 (n=6). Without illumination, 
no toxicity was observed on keratocytes using different concentrations of the 
photosensitizer Ce6 up to 2 µM. After dark incubation with 64 µM of Ce6, a 
decreased viability on keratocytes was obtained (P=0.02) compared to control. 
Following PDT, with Ce6 concentrations higher than 100 nM, keratocyte viability 
was significantly decreased (P<0.01) (Alamar blue assay). Viability has shown even a 
decreasing trend with increasing concentrations of Ce6 higher than the above value. 
No survival was observed with concentrations of 2 µM and greater.  
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Figure 10. Viability of human keratocytes following PDT using Alamar blue assay. 
24 hours after treatment, application of increasing concentrations of Ce6 without 
illumination did not show an impact on keratocyte viability up to 2 µM, but dark 
toxicity of keratocytes could be detected at 64 µM concentration of Ce6 without 
illumination (*P=0.019, compared to control). With illumination, with increasing 
concentrations of Ce6, keratocyte viability decreased significantly from 100 nM 
concentration of Ce6 (*P<0.001, compared to control). 
 
3.3.2   HCECs viability 
Results of the Alamar blue assay are shown at Figure 11 (n=6). Without illumination, 
no toxicity was observed on HCECs using different concentrations of the 
photosensitizer Ce6 up to 500 nM. Following PDT, with Ce6 concentrations higher 
than 150 nM, HCECs viability was significantly decreased (P<0.01). Viability 
showed a decreasing trend with increasing concentrations of Ce6 higher than the 
above value.   
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Figure 11. Viability of HCECs following PDT using Alamar blue assay. 24 hours 
after treatment, application of increasing concentrations of Ce6 without illumination 
did not show an impact on HCECs. With illumination, with increasing concentrations 
of Ce6, HCECs viability decreased significantly from concentrations of 150 nM of 
Ce6 (*P<0.001, compared to control). 
 
3.4    Total DNA content and apoptosis 
 
3.4.1   Keratocyte total DNA content 
Using the APO-DIRECTTM Kit, illumination without application of the 
photosensitizer Ce6 or application of Ce6 only had no impact on keratocyte total 
DNA content (Figure 12, n=3). Using concentrations higher than 250 nM of Ce6, 
keratocyte total DNA content was significantly decreased (P<0.01) following 
illumination showing a decreasing trend with increasing Ce6 concentrations. 
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Figure 12. Total DNA content of human keratocytes following PDT using 
Apo-Direct kit assay. Without illumination, keratocyte total DNA content remained 
unchanged with different concentrations of Ce6. With illumination, total DNA content 
of keratocytes decreased significantly from concentrations of 250 nM of Ce6 and 
higher (*P<0.01, compared to control).  
 
3.4.2   Keratocyte apoptosis 
With the APO-DIRECTTM Kit, the apoptotic keratocytes could not be detected after 
exposure to different Ce6 concentrations in the absence of illumination, or with 
illumination only. A significant increase of the percentage of apoptotic cells could be 
detected at 500 nM Ce6 concentration (P<0.01) (Figure 13, n=3). 
 
 
 
 
 
0
30
60
90
0  50 150 250 350 500 2000 64000
Ce6 concentration (nM)
T
ot
al
 D
N
A
 (%
)
 - Illumination  + Illumination
* * * * * 
RESULTS                                                          36 
  
 
 
 Figure 13. Apoptosis of human keratocytes after PDT using Apo-Direct kit assay. 
Without illumination, the number of apoptotic keratocytes did not increase 
significantly using different concentrations of Ce6. With illumination, the number of 
apoptotic keratocytes increased significantly at 500 nM Ce6 concentration (*P<0.01). 
At 2 µM and 64 µM concentration, most of the cells were necrotic, and only a small 
amount of DNA-labeling solution could be incorporated into the non-necrotic cells.  
 
3.4.3   HCECs total DNA content 
Using Apo-Direct kit assay, illumination without application of the photosensitizer 
Ce6 or application of Ce6 only, had no impact on HCECs total DNA content (Figure 
14, n=6). Using concentrations higher than 150 nM of Ce6, HCECs total DNA 
content was decreased (P<0.05) following illumination. Furthermore, a decreasing 
trend was shown with increasing Ce6 concentrations.  
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Figure 14. Total DNA content of HCECs following PDT using Apo-Direct kit assay. 
Without illumination, HCECs total DNA content remained unchanged with different 
concentrations of Ce6. With illumination, total DNA content of HCECs decreased 
from concentrations higher than 150 nM of Ce6 (#P =0.043, *P<0.01, compared to 
control).  
 
3.4.4   HCECs apoptosis 
With Apo-Direct kit assay, the apoptotic HCECs could not be detected after exposure 
to different Ce6 concentrations in the absence of illumination, or with illumination 
only. An increase of the percentage of apoptotic cells could, however, be detected 
from concentrations higher than 250 nM of Ce6 (P<0.01) (Figure 15, n=6). 
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Figure 15. Percentage of apoptotic HCECs after PDT using Apo-Direct kit assay. 
Without illumination, the number of apoptotic HCECs did not increase significantly 
using different concentrations of Ce6. With illumination, the number of apoptotic 
HCECs increased significantly from 250 nM Ce6 concentration (*P<0.01, compared 
to control). 
 
3.5    Proliferation 
 
3.5.1   Keratocyte proliferation 
Two hours after PDT, there was no significant change in keratocyte proliferation 
using different Ce6 concentrations, with or without illumination. Twenty-four hours 
following PDT, the proliferation of cells was inhibited significantly with 250 nM Ce6 
concentration (P=0.01) compared to control (Figure 16, n=4).  
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Figure 16. Proliferation of human keratocytes following PDT using BrdU Cell 
Proliferation Assay Kit. 24 hours after illumination, the proliferation of keratocytes 
was significantly inhibited using 250 nM Ce6 concentration (*P=0.013) compared to 
control, while it was unchanged 2 hours after PDT. 24h before illumination group was 
tested as a starting point in cell growth under the same condition without PDT 
treatment. (-) as without illumination and (+) as with illumination. 
 
3.5.2   HCECs proliferation 
Two hours after PDT, there was no significant change in HCECs proliferation using 
different Ce6 concentrations without illumination, or illumination only. Two hours 
following PDT the proliferation of cells was inhibited significantly at 250 nM Ce6 
concentration (P<0.01) (Figure 17, n=6), and twenty-four hours after PDT at 100 nM 
(P=0.019) and 250 nM (P<0.01) concentrations of Ce6 compared to control. 
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Figure 17. Proliferation of HCECs following PDT using BrdU Cell Proliferation 
Assay Kit. 24 hours after illumination for 13 min, the proliferation of HCECs was 
significantly inhibited using 100 nM (*P=0.019) and 250 nM (*P<0.01) Ce6 
concentration, and it was decreased at 250 nM Ce6 concentration (*P<0.01) 2 hours 
after illumination compared to control. (-) Without illumination, (+) With illumination 
for 13 min.  
 
3.6    CD34 and α-SMA expression of keratocytes 
 
CD34 and α-SMA expression of keratocytes 24 hours following PDT are summarized 
in Figures 18 and 19 (n=8). Using Ce6 or illumination only, CD34 and α-SMA 
expression of the cells did not change significantly. Twenty-four hours after PDT, the 
expression of CD34 has shown an increasing trend with increasing concentration of 
Ce6. The percentage of α-SMA positive keratocytes decreased significantly (P=0.02) 
compared to controls at 250 nM concentration of Ce6 following illumination.  
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Figure 18. CD34 expressions of human keratocytes 24 hours after PDT. Following 
illumination, the percentage of CD34 positive keratocytes has shown an increasing 
trend with increasing Ce6 concentrations, however, there was no significant 
difference compared to controls.  
 
 
Figure 19. α-SMA expression of human keratocytes 24 hours after PDT. Following 
illumination, the percentage of α-SMA positive keratocytes has shown a decreasing 
trend with increasing Ce6 concentrations. At 250 nM Ce6 concentration, the 
percentage of α-SMA positive cells decreased significantly following illumination 
compared to controls (*P=0.02). 
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3.7    Growth factor secretion of keratocytes  
 
Five hours after PDT, the concentrations of KGF, FGFb, VEGF, HGF and TGFβ1 are 
summarized at Table 2 (n=5). Following PDT, using 100 nM Ce6 and illumination, 
the mean FGFb concentration was 5.26 ± 1.49 pg/µg protein in the supernatant of 
cultured keratocytes. This was significantly higher than FGFb concentration at 
untreated keratocyte cultures (P<0.01). The FGFb secretion also increased using 
illumination only compared to control (P<0.01). Five hours following PDT, the 
secretion of HGF was significantly lower than in untreated controls (P=0.01) (Figure 
20, n=5). In addition, HGF concentration was significantly lower following Ce6 
exposure and illumination, as compared to illumination alone (P=0.03). 
We could not detect changes in the secretion of KGF and VEGF of keratocytes with 
or without illumination five hours following PDT. FGFb, HGF, KGF, VEGF 
concentrations using only Ce6 or illumination did not differ significantly from 
untreated controls. The secretion of TGFβ1 was under the measurement limit in the 
treated and untreated cell cultures five hours after PDT. 
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Groups Control 
  Ce6 + 
Illumination 
* 
p-value 
** 
p-value 
*** 
p-value Ce6 Illumination 
KGF 1.33 ± 0.42 1.20 ± 0.21 1.38 ± 0.32 1.40 ± 0.37 0.51 0.49 
 
0.88 
FGFb 
 
3.47 ± 0.94 
 
4.06 ± 1.02 
 
4.06 ± 1.22 
 
5.26 ± 1.49 
 
< 0.01 
 
< 0.01 
 
0.24 
VEGF 
 
1.38 ± 0.76 
 
1.23 ± 0.42 
 
1.10 ± 0.58 
 
1.05 ± 0.96 
 
0.37 
 
0.27 
 
0.75 
HGF 
 
0.43 ± 0.23 
 
0.39 ± 0.27 
 
0.39 ± 0.27 
 
0.24 ± 0.25 
 
0.35 
 
0.01 
 
0.03 
TGFβ1 n.d. n.d. n.d. n.d. n/a n/a n/a 
 
Table 2. Concentration (pg/µg protein) of different growth factors in keratocyte 
cultures five hours after PDT. Values indicate mean ± SD. 
* p-values indicate the difference between “Control” versus “Illumination alone” 
groups (Mann-Whitney U test). 
** p-values indicate the difference between “Control” versus “Ce6 + Illumination” 
groups (Mann-Whitney U test).  
*** p-values indicate the difference between “Illumination alone” versus “Ce6 + 
Illumination” groups (Mann-Whitney U test). 
Significant values are shown in bold. 
n.d. = not detectable and n/a = not applicable. 
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Figure 20. Concentration of different growth factors 5 hours following PDT. 
Significant differences are indicated. 
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Table 3 and Figure 21 (n=5) display concentrations of KGF, FGFb, VEGF, HGF and 
TGFβ1 24 hours after PDT. Twenty-four hours following PDT, the secretion of KGF 
was significantly lower than in untreated control (P<0.01). The KGF expression also 
decreased with illumination only compared to control cells (P<0.01). 
The secretion of FGFb, VEGF, HGF and TGFβ1 did not change significantly 
compared to untreated control keratocyte cultures for this time point. However, 
TGFβ1 concentration was significantly lower following illumination only, than after 
Ce6 exposure and illumination (P=0.01). Similarly, VEGF concentration was 
significantly lower after illumination, as compared to that following Ce6 exposure and 
illumination (P<0.01). 
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Groups Control 
  Ce6 + 
Illumination 
* 
p-value 
** 
p-value 
*** 
p-value Ce6 Illumination 
KGF 6.57 ± 0.57 6.85 ± 0.56 5.37 ± 0.55 5.67 ± 0.63 <0.01 <0.01 
 
0.23 
FGFb 5.51 ± 3.83 5.88 ± 2.79 4.72 ± 2.92 4.18 ± 1.74 0.39 0.26 0.64 
VEGF 7.74 ± 4.21 7.38 ± 3.64 5.95 ± 3.35 9.01 ± 3.43 0.21 0.16 <0.01 
HGF 1.59 ± 1.52 1.34 ± 1.08 1.72 ± 1.69 1.61 ± 1.36 0.99 0.61 0.89 
TGFβ1 3.40 ± 1.53 3.21 ± 1.11 2.83 ± 1.30 3.76 ± 1.17 0.19 0.32 0.01 
 
Table 3. Concentration (pg/µg protein) of different growth factors in keratocyte 
cultures twenty-four hours after PDT. Values indicate mean ± SD. 
* p-values indicate the difference between “Control” versus “Illumination alone” 
groups (Mann-Whitney U test). 
** p-values indicate the difference between “Control” versus “ Ce6 + Illumination” 
groups (Mann-Whitney U test).  
*** p-values indicate the difference between “Illumination alone” versus “Ce6 + 
Illumination” groups (Mann-Whitney U test). 
Significant values are shown in bold. 
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Figure 21. Concentration of different growth factors 24 hours following PDT. 
Significant differences are indicated. 
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4    DISCUSSION 
  
4.1    Impact of PDT on viability, apoptosis, proliferation and 
activation of human keratocytes 
 
In recent years, PDT became an important treatment modality for therapy resistant 
infectious keratitis. The ORS produced during PDT result in apoptosis or even 
necrosis of the cells and tissues. The possible adverse effects on normal mammalian 
cells or tissues are the limiting factors of the use of PDT. Nevertheless, PDT may also 
result in activation of keratocytes or even modification of the local immune response 
to pathogens. This is the first study illustrating the viability, apoptosis and 
proliferation of human keratocytes in vitro following PDT using a porphyrin 
derivative, in order to evaluate the “tolerance” of normal keratocytes to PDT. Ce6, 
with its high photosensitizing efficacy may be a photosensitizer of choice in localized 
infections for the future. 92  
In the present in vitro study we demonstrated that PDT using the photosensitizer Ce6 
reduces the viability of keratocytes in a dose-dependent manner and induces apoptosis 
of the cells. We could determine that the cell cohesion was reduced and the clusters of 
cells became smaller with increasing concentrations of Ce6 following PDT. Cell 
viability was decreased from 100 nM Ce6 concentration using Alamar blue assay, and 
total DNA content of the cells decreased from 250 nM Ce6 concentration using the 
APO-DIRECTTM Kit following illumination. Accordingly, the percentage of apoptotic 
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cells also increased from 250 nM concentration of Ce6 after illumination, and a 
significant increase at 500 nM concentration of Ce6 was reached.  
Corneal collagen crosslinking (CLX) uses riboflavin as photosensitizer and UVA light 
for illumination/excitation. CLX increases effectively the biomechanical rigidity of 
the cornea in order to delay or stop the progression of keratoconus. 123 The potential 
of riboflavin to heal bacterial or acanthamoeba keratitis has been shown recently. 119 
Using collagen crosslinking, Wollensak et al. 124 could detect similar impact on 
keratocytes in vitro with an abrupt cytotoxic effect (Trypan blue and 
Yopro-fluorescence staining).  
The proliferation of keratocytes was decreased at 250 nM Ce6 concentration 24 hours 
after PDT, in our study. In contrast, at a later time point, 6 months following corneal 
crosslinking in a histological study, a significant increase in keratocyte proliferation 
could be shown using Ki-67 staining. 125 In our opinion, the induced keratocyte 
proliferation detected 6 months after CLX may be part of the long-term repair 
mechanisms after the treatment. 
The most conspicuous finding of our study is that using subcytotoxic concentrations 
of the photosensitizer Ce6, CD34 expression will be slightly upregulated and α-SMA 
expression downregulated in keratocytes 24 hours following PDT. With other words, 
hematopoietic stem cell activation will be tendentially promoted, myofibroblastic 
transformation inhibited through PDT.  
CD34 is a surface glycophosphoprotein expressed on lymphohemotopoietic stem cells, 
vascular endothelial cells, embryonic fibroblasts and fibroblast-like dendritic cells in 
connective tissues. 126 Sosnová et al. 127 reported that the larger population of bone 
marrow derived leukocytes in the corneal stroma are CD34 positive. Studies of Dua et 
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al. 128 confirmed that CD34 positive keratocytes are multipotent hemopoetic stem 
cells.  
Increased α-SMA expression is detected in myofibroblasts, not in keratocytes. 129 
Corneal myofibroblasts are determinant in corneal wound healing and contraction. 
Recent studies have shown that corneal myofibroblasts also have an important role in 
bacterial and viral clearance by the expression of toll-like receptor (TLR), which is a 
receptor for lipopolysaccharides produced by bacteria. 130 It was also described 
previously, that CD34 expression in human keratocytes is downregulated during 
myofibroblast differentiation. 131 The role of CD34 positive hemopoetic stem cells 
may be to replenish tissue resident macrophages and plasmacytoid dendritic cells. 
132,133 Studies on the function of CD34 suggest that it may also play a role in 
cytoadhesion, and signalling related to differentiation and proliferation. 134 
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4.2    Growth factor secretion of human keratocytes following PDT 
 
PDT using Ce6 decreases viability and proliferation, suppresses myofibroblastic 
transformation and triggers apoptosis of human keratocytes, which may also lead to 
inflammatory cell response, in vitro. 135, 136 The impact of PDT on secretion of growth 
factors of human keratocytes was analyzed in the present study. 
PDT using subcytotoxic concentration of Ce6 increases FGFb and decreases HGF 
secretion of keratocytes 5 hours after treatment. Twenty-four hours following PDT 
concentration of both growth factors normalizes in culture, however, the 
concentration of KGF decreases. A limitation of our study is that using ELISA, only 
secreted growth factors were measured and total protein or mRNA analysis was not 
performed. 
It is known, that mRNA coding for TGFβ1, FGFb, KGF, and HGF are represented in 
corneal cells. 137-139 These growth factors are associated to paracrine interactions 
between different cell types of the cornea, especially with an impact on corneal 
epithelial cells.  
FGFb promotes angiogenesis, cell proliferation and migration. PDT increased the 
expression of FGFb five hours after exposure to 100 nM concentration of Ce6 
combined with 370 nm light, and with that, may induce angiogenesis in the cornea 
and keratocyte proliferation acting in an autocrine manner. Furthermore FGFb induces 
the differentiation of keratocytes into a fibroblastic phenotype. 129 Interestingly, Ley et 
al. 140 also found increased FGFb secretion in the cornea of Monodelphis domestica 
after 360 nm ultraviolet light. 
HGF is known to delay the process of reepithelialization. The decrease of HGF five 
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hours after PDT may result in decreased proliferation and migration of both epithelial 
cells and keratocytes acting as a paracrine and autocrine regulator. 141 HGF also 
induces myofibroblastic transformation of keratocytes. With decreased HGF secretion, 
myofibroblastic tranformation may be inhibited after PDT. In accordance with that, 
we have also found decreased alpha-smooth actin expression of keratocytes using 250 
nM concentration of Ce6, following PDT. Lee et al. 142 reported on the inhibitory 
effect of HGF on apoptosis of bovine pulmonary artery endothelial cells. Our current 
findings indicate that the decreased HGF secretion of keratocytes in cell culture is too 
low to prevent them from apoptosis five hours after PDT. 
Some authors reported on increased KGF mRNA expression in wounded mouse 
corneas. 143,144 In contrast, our study could not determine a significant impact of PDT 
on KGF secretion 5 hours following treatment, but its secretion decreased after 24 
hours. KGF was reported to accelerate corneal epithelial wound healing in vivo, 145 
which could be delayed 24 hours after PDT, with decreased KGF secretion.  
Interestingly, following a slight decrease of VEGF secretion 5 hours after PDT, its 
concentration increased 24 hours after treatment. These results indicate that PDT may 
promote corneal haem- and lymphangiogenesis through the vascular endothelial 
growth factor one day following treatment. 146 
It has been previously reported, that TGFβ1 induces CD34 expression of keratocytes 
in cell culture. 131 TGFβ1 also promoted myofibroblastic transformation of 
keratocytes following corneal injury. 147 Honma et al. 148 have reported that TGFβ1 
and TGFβ2 also inhibit the promotion of KGF and HGF dependent cell proliferation. 
Five hours following PDT, we could not detect significant secretion of TGFβ1 and 24 
hours after PDT its secretion was only slightly increased.  
This is also in accordance with our previous measurements: at 100 nM Ce6 
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concentration, CD34 and α-SMA expression of keratocytes did not change 
significantly after 24 hours. Our study could not determine a decisive role of TGFβ1 
secretion on CD34 expression or myofibroblastic transformation of keratocytes 5 and 
24 hours after PDT.  
Interestingly, using illumination or the photosensitizer Ce6 separately, we did not 
detect changes in viability, apoptosis, CD34 or alpha smooth-actin expression of 
keratocytes, at our previous measurements. 149,150 In contrast, FGFb secretion 5 hours 
following the use of illumination only and KGF secretion 24 hours after illumination 
only significantly differed from controls. In addition, using illumination, 5 hours after 
treatment, HGF secretion was significantly decreased at 100 nM Ce6 concentration 
compared to illumination alone, and after 24 hours, VEGF and TGFβ1 secretion was 
significantly increased. It is known from previous studies that the use of a 
photosensitizer or illumination separately may have an impact on growth factor 
secretion of the cells; however, the detailed molecular mechanisms are still to be 
clarified. 151 
DISCUSSION                                                       54 
  
 
4.3    Impact of PDT on viability, apoptosis and proliferation of 
HCECs 
 
HCECs located as a single cell layer at the posterior surface of the cornea play a 
crucial role in maintaining corneal transparency. Therefore, using PDT in keratitis, 
cytotoxic effects on HCECs should be as small as possible. Corneal endothelial cells 
are also much more sensible for stress than epithelial cells 152 or keratocytes 153,154 or 
other cell types. 155,156  
The last few years Ce6 is widely used as second-generation photosensitizer. The main 
advantages of Ce6 are its low toxicity, easy synthesis and production, fast and 
sufficiently selective accumulation in target tissue and high photosensitizing efficacy. 
92 Penetration depth of the photosensitizer Ce6 in the cornea depends on 
photosensitizer concentration, exposition time and room temperature. After removal 
of the corneal epithelium using 450 µM of Ce6 for 15 minutes at 35 ˚C, Ce6 
penetrates until 400 µm stromal depth.157 
In the present study we demonstrated that PDT reduces the viability of HCECs in a 
dose-dependent manner and induces apoptosis of the cells. Alamar blue assay has 
shown a significant cytotoxic effect on corneal endothelial cells after application of at 
least 150 nM concentration of Ce6 and 13 minutes of red-light illumination. There 
was a significant increase in the percentage of apoptotic HCECs using at least 250 nM 
Ce6 concentration and illumination. 
In addition, we also determined that proliferation of HCECs was inhibited 2 and 24 
hours after exposure to illumination using 250 nM concentration of Ce6. As our 
HCEC line was an immortalized human corneal endothelial cell line, 158 with a 
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different manner of proliferative capacity compared to primary HCECs, the impact of 
our study is limited. Nevertheless, we hypothesized that the decreased cell 
proliferation may be in relation to the significant HCEC loss through apoptosis at this 
concentration.  
Corneal collagen crosslinking is a new technique to increase effectively the 
biomechanical rigidity of the cornea and to delay or stop the progression of 
keratoconus. 123,159 Collagen crosslinking may also be interpreted as a special type of 
PDT, which uses riboflavin as photosensitizer and ultraviolet-A (UVA) light (370 nm) 
for illumination. The cytotoxic effect on corneal endothelial cells is already known by 
the use of relatively high UVA irradiance (4 mW/cm2) or a combined UVA (0.35 
mW/cm2) treatment and the use of 0.025% riboflavin solution (500 µM) in vitro. 160  
An in vivo study of rabbit corneas 161 has also demonstrated a cytotoxic effect on 
corneal endothelium using the standard surface irradiance of 3.0 mW/cm2 combined 
with an application of 0.1% riboflavin-5-phosphate and 20% dextran T-50 on the 
cornea. In our study, we observed a significant cytotoxic effect on human corneal 
endothelial cells using an irradiance of 31 mW/ cm2 (670 nm) for 13 minutes 
combined with 150 nM concentration of Ce6 in vitro. The difference may originate 
from the distinct photodynamic efficacy of both photosensitizers.  
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4.4    Conclusions and outlook to the future 
 
With increasing resistance of microorganisms to antibiotics, alternative therapeutic 
options are required in the treatment of infectious keratitis. Some authors claim that 
“photodynamic therapy” (PDT) is one potential therapeutic option. 97 Since the first 
case report of Micelli Ferrari et al. 162 in 2009 on succesful treatment of Eschericia 
coli keratitis using riboflavin-UVA-crosslinking therapy (as PDT), the number of 
patients treated using his therapeutic option increases. 97 
Lethal photosensitization is a process by which a photosensitizer is activated by light 
of appropriate wavelenght resulting in the production of cytotoxic reactive oxygen 
species, which then kill the target cell. However, this also means that commensal 
bacteria and host tissues could be adversely affected.  
In our work we determined that: 
l PDT using Ce6 decreases viability and proliferation, suppresses myofibroblastic 
transformation and triggers apoptosis of human keratocytes, in vitro. 
l PDT triggers FGFb and inhibits HGF secretion of human keratocytes 5 hours and 
inhibits KGF secretion 24 hours following treatment. 
l PDT using Ce6 decreases viability and proliferation, and also triggers apoptosis 
of HCECs, in vitro. 
In human keratocyte and endothelial cell cultures - using a standard irradiation dose - 
we may determine a treshold cytotoxic concentration for the photosensitizer 
(increased apoptotosis). 124,160 Using the same standard irradiation dose, in order to 
reach 90% killing rate of SA, SE or PA in vitro, application of about 400 x of the 
cytotoxic treshold concentration of the photosensitiser is necessary. 63 This condition 
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occurs using the photosensitizer riboflavin and UVA light illumination, 63,124,160 or 
even with porphyrins as photosensitizer and red light excitation. 114 Therefore, it is 
important to develop a treatment method that could specifically target the pathogenic 
organisms without causing any adverse effects on the host tissue. 
For PDT, one method of achieving this is to conjugate the photosensitizer to an 
antibody raised directly against microorganisms. Photosensitizers that have been up to 
now conjugated to antibodies include porphyrins, sulfonated aluminium 
phthalocyanine and hematoporphyrin. 163 As an example, polycationic conjugates 
between poly-L-lysine chains and the porphyrin Ce6 are particularly suited to fight 
both Gram positive or negative bacteria and also funghi. 164 
With antibody-targeted photosensitisation it was possible to kill 99% of MRSA using 
only 2.5 µg/ml of the photosensitizer Ce6, which concentration is only 18 x above the 
cytotoxic treshold of keratocytes. 97,163 In addition, the antibody-targeted 
photosensitiser with specific bindig to pathogens may cause even less damage to 
human cells. 164 
Antibody-targeted photosensitisation may open a new horison in the treatment of 
infectious keratitis. Development of aspecific or even specific antibody- 
photosensitizer conjugates may offer a further treatment alternative for therapy 
resistant cases. 
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